XML 37 R19.htm IDEA: XBRL DOCUMENT
v3.24.0.1

BENEFITS PAYABLE | 12 Months Ended
--- | ---
Dec. 31, 2023
Insurance [Abstract] |
BENEFITS PAYABLE | BENEFITS PAYABLE On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the years ended December 31, 2023, 2022 and 2021:
|  | 2023 |  | 2022 |  | 2021
|  | (in millions)
Balances at January 1 |  | $ | 9,264 |  |  | $ | 8,289 |  |  | $ | 8,143 |
Acquisitions |  | 62 |  |  | — |  |  | 42 |
Incurred related to: |  |  |  |  |  |
Current year |  | 89,266 |  |  | 76,105 |  |  | 70,024 |
Prior years |  | (872) |  |  | (415) |  |  | (825) |
Total incurred |  | 88,394 |  |  | 75,690 |  |  | 69,199 |
Paid related to: |  |  |  |  |  |
Current year |  | (79,545) |  |  | (67,287) |  |  | (62,149) |
Prior years |  | (7,934) |  |  | (7,428) |  |  | (6,946) |
Total paid |  | (87,479) |  |  | (74,715) |  |  | (69,095) |
Balances at December 31 |  | $ | 10,241 |  |  | $ | 9,264 |  |  | $ | 8,289 |
The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net incurred claims amounts. At December 31, 2023 and 2022, benefits payable included IBNR of approximately $6.6 billion and $5.7 billion, primarily associated with claims incurred in each respective year. The cumulative number of reported claims as of December 31, 2023 was approximately 200.0 million for claims incurred in 2023, 182.4 million for claims incurred in 2022, and 173.7 million for claims incurred in 2021. Amounts incurred related to prior years vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development). As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $872 million in 2023, $415 million in 2022, and $825 million in 2021. The medical claims reserve development for 2023, 2022, and 2021 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. The favorable development recognized in 2023 and 2021 primarily resulted from trend factors developing more favorably than originally expected as well as for 2021 completion factors developing faster than expected. The favorable development recognized in 2022 resulted primarily from completion factors remaining largely unchanged, resulting in lower overall development as compared to 2023 and 2021. Incurred and Paid Claims Development The following discussion provides information about incurred and paid claims development as of December 31, 2023, net of reinsurance, as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts. The information about incurred and paid claims development for the years ended December 31, 2022 and 2021 is presented as supplementary information. Claims frequency is measured as medical fee-for-service claims for each service encounter with a unique provider identification number. Our claims frequency measure includes claims covered by deductibles as well as claims under capitated arrangements. Claim counts may vary based on product mix and the percentage of delegated capitation arrangements. The following tables provide information about incurred and paid claims development as of December 31, 2023, net of reinsurance.
|  | Incurred Claims, Net of Reinsurance |  |
|  | For the Years Ended December 31, |  |  |  |
Claims Incurred Year |  | 2021 Unaudited |  | 2022 Unaudited |  | 2023 |  |
|  | (in millions) |  |  |  |
2021 & Prior |  | $ | 70,066 |  |  | $ | 69,698 |  |  | $ | 69,484 |  |  |  |  |
2022 |  |  |  | 76,105 |  |  | 75,447 |  |  |  |  |
2023 |  |  |  |  |  | 89,328 |  |  |  |  |
Total |  |  |  |  |  | $ | 234,259 |  |  |  |  |
|  | Cumulative Paid Claims, Net of Reinsurance
|  | For the Years Ended December 31,
Claims Incurred Year |  | 2021 Unaudited |  | 2022 Unaudited |  | 2023
|  | (in millions)
2021 & Prior |  | $ | 62,149 |  |  | $ | 69,252 |  |  | $ | 69,484 |
2022 |  |  |  | 67,287 |  |  | 74,989 |
2023 |  |  |  |  |  | 79,545 |
Total |  |  |  |  |  | 224,018 |
All outstanding benefit liabilities before 2021, net of reinsurance |  | N/A
Benefits payable, net of reinsurance |  | $ | 10,241 |
For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.

X
- References No definition available. + Details
Name: | us-gaap_InsuranceAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479838/944-20-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//944/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(4)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479584/944-310-50-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)(4)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479584/944-310-50-3 + Details
Name: | us-gaap_InsuranceDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration